New marker flags DNA repair response to platinum therapy

Share this article:

A newly discovered genetic marker of DNA damage may be able to predict which patients with triple-negative breast cancer or serous ovarian cancer will respond to platinum-based chemotherapy drugs such as cisplatin or carboplatin. 

“We currently do not have any targeted therapies for patients with triple-negative breast cancer, so if these laboratory findings are confirmed and an assay is created to predict sensitivity to drugs that target defective DNA repair, it would be a major step forward,” affirmed Andrea Richardson, MD, PhD, in a statement issued by the American Association for Cancer Research. Richardson, an assistant professor of medicine at Dana-Farber Cancer Institute in Boston, Massachusetts, was the lead pathologist on the study that yielded the new marker, telomeric allelic imbalance (tAI).

DNA repair status is known to be a predictor of sensitivity to therapy and thus prognosis: Whereas some cancer cells can repair DNA molecules that have been damaged by drug or radiation therapy, other cancer cells have lost this capacity, making them vulnerable to DNA-damaging agents. However, measurements of DNA repair status have been slow to arrive. Now, tAI appears to identify breast and ovarian cancer cells that can't repair the DNA damage caused by platinum drugs. This information can be used to distinguish patients who can be treated effectively with a single platinum-based drug and avoid the toxicities of other chemotherapy combinations.

Richardson and associates made the discovery while correlating genomic signatures in cell lines and tumors to platinum sensitivity. The researchers found that in some patients with serous ovarian cancer or triple-negative breast cancer (the latter is characterized by a lack of estrogen, progesterone, and HER2 receptors, making the tumors unresponsive to targeted treatments that block those receptors), tumor cells exhibited a high number of chromosome regions with an allelic imbalance that extended to the telomeres (tips of the chromosomes). This pattern was a strong indicator of defective DNA damage repair, predicting response to cisplatin therapy. In addition, the investigators found an inverse relationship between tAI level and BRCA1 expression in triple-negative breast cancer.

The report by Richardson and colleagues appears in Cancer Discovery (2012;2[4]:366-375).



Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.